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We tested the hypothesis that treatment of rats with curcumin prevents sepsis-induced muscle protein degradation. In addition,
we determined the inﬂuence of curcumin on diﬀerent proteolytic pathways that are activated in septic muscle (i.e., ubiquitin-
proteasome-, calpain-, and cathepsin L-dependent proteolysis) and examined the role of NF-κB and p38/MAP kinase inactivation
in curcumin-induced inhibition of muscle protein breakdown. Rats were made septic by cecal ligation and puncture or were
sham-operated. Groups of rats were treated with three intraperitoneal doses (600mg/kg) of curcumin or corresponding volumes
ofsolvent.Proteinbreakdownratesweremeasuredasreleaseoftyrosinefromincubatedextensordigitorumlongusmuscles.Treat-
ment with curcumin prevented sepsis-induced increase in muscle protein breakdown. Surprisingly, the upregulated expression of
the ubiquitin ligases atrogin-1 and MuRF1 was not inﬂuenced by curcumin. When muscles from septic rats were treated with cur-
cumin in vitro, proteasome-, calpain-, and cathepsin L-dependent protein breakdown rates were reduced, and nuclear NF-κB/p65
expression and activity as well as levels of phosphorylated (activated) p38 were decreased. Results suggest that sepsis-induced
muscle proteolysis can be blocked by curcumin and that this eﬀect may, at least in part, be caused by inhibited NF-κB and p38
activities. The results also suggest that there is not an absolute correlation between changes in muscle protein breakdown rates and
changes in atrogin-1 and MuRF1 expression during treatment of muscle wasting.
Copyright © 2008 Vitaliy Poylin et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Increased breakdown of muscle proteins, in particular
the myoﬁbrillar proteins actin and myosin, is a com-
mon metabolic consequence of sepsis and other critical ill-
ness, resulting in muscle wasting, weakness, and fatigue
[1, 2]. Although calpain- and cathepsin L-dependent prote-
olytic mechanisms are activated in atrophying muscle [3–6],
ubiquitin-proteasome-dependent proteolysis plays a partic-
ularly important role in muscle wasting [7–9]. A substantial
increase in the expression of the muscle-speciﬁc ubiquitin
ligases atrogin-1 (MAFbx) and MuRF1 in various catabolic
conditions supports the important role of the ubiquitin-
proteasome pathway in loss of muscle mass [10–12].
The molecular regulation of muscle wasting is complex
and involves activation of various transcription factors and
nuclear cofactors regulating genes in diﬀerent proteolytic
pathways reviewed in [13]. Among muscle wasting-related
transcription factors, NF-κB has attracted much recent at-
tention. Thus, there is evidence that NF-κBi sa c t i v a t e di n
skeletal muscle during sepsis [14] and in cultured myotubes
treatedwithproinﬂammatorycytokines[15,16].Furtherev-
idence for a role of NF-κB in muscle atrophy was found in a
recent study in which muscle-speciﬁc overexpression of ac-
tivated IkB kinase β (IKKβ) in mice resulted in phosphory-
lation and degradation of the inhibitory protein IkBα,a c t i -
vation of NF-κB, increased proteasome-dependent protein
breakdown, and muscle atrophy [17].
Curcumin (diferuloylmethane), a component of the
spice turmeric (Curcuma longa) and responsible for the yel-
low color of curry [18, 19], possesses anti-inﬂammatory
properties that are at least in part due to inhibition of
NF-κB[ 20, 21]. In recent studies, the eﬀects of curcumin
on the catabolic response in skeletal muscle during various
muscle-wasting conditions were examined and apparently
conﬂicting results were observed. For example, treatment2 Mediators of Inﬂammation
of rodents with curcumin did not prevent muscle atro-
phy caused by muscle unloading [22], experimental cancer
[23, 24], or muscular dystrophy [25]. In contrast, treatment
of cultured myotubes with curcumin prevented the increase
in protein degradation caused by a cachectic factor puri-
ﬁ e df r o me x p e r i m e n t a lt u m o r si nm i c e[ 24]. In other ex-
periments, treatment of mice with curcumin prevented the
loss of muscle weight and muscle protein caused by injection
of lipopolysaccharide (LPS) [26]. Interestingly, in the same
study [26], the LPS-induced upregulation of atrogin-1, but
not that of MuRF1, was inhibited by curcumin.
The inﬂuence of curcumin on the catabolic response in
skeletal muscle caused by sepsis is not known. In the present
study, we tested the eﬀects of curcumin on muscle proteoly-
sis and the expression of atrogin-1 and MuRF1 in rats made
septic by cecal ligation and puncture (CLP). This is a clini-
callyrelevantexperimentalmodelresemblingthesituationin
manysurgicalpatientswithsepsiscausedbyintra-abdominal
abscess,devitalizedtissue,andamixedaerobicandanaerobic
bacterial ﬂora in the peritoneal cavity and the blood stream
[27]. We found in previous reports that CLP in rats was as-
sociated with an early activation of NF-κB in skeletal mus-
cle [14], accelerated ubiquitin-proteasome-dependent mus-
cle proteolysis [28], and a substantial increase in atrogin-1
and MuRF1 mRNA levels [12]. In the present study, treat-
ment of septic rats with curcumin reduced muscle protein
breakdown rates and NF-κB activity but, surprisingly, did
not decrease the expression of atrogin-1 and MuRF1.
2. MATERIALS AND METHODS
2.1. Experimentalanimals
Sepsis was induced in male Sprague-Dawley rats (50–70g)
by CLP as described previously [12, 27, 28]. Other rats un-
derwent sham-operation consisting of laparotomy and ma-
nipulation, but no ligation or puncture, of the cecum. Saline
(10mL/100gbodyweight)wasadministeredsubcutaneously
on the back of each rat at the time of surgery to prevent
hypovolemia and septic shock. The importance of an ade-
quate volume resuscitation to prevent hypovolemia and sep-
tic shock after CLP in rats is well documented [27, 29].
The use of 10mL/100g body weight is based on several pre-
vious reports from our laboratory [6, 12, 14, 28, 30]a s
well as unpublished observations in this laboratory show-
ing that this volume contributes to the prevention of septic
shock. Animals had free access to water, but food was with-
held after the surgical procedures (both sham-operation and
CLP) to avoid the inﬂuence of diﬀerences in food intake on
metabolic changes between sham-operated and septic rats.
Small rats were used because their lower extremity muscles
are thin enough to allow for measurement of protein break-
down rates during in vitro incubation with maintained vi-
ability. The septic model used here is associated with a re-
producible and substantial increase in muscle protein break-
down [12, 28, 30].
Two series of experiments were performed. In the ﬁrst
series of experiments, rats were treated in vivo with dif-
ferent amounts (described in Section 3)o fc u r c u m i n( C a y -
man Chemical Co, Ann Arbor, Mich, USA) administered in-
traperitoneally 1hour before and 8 and 15hours after sham-
operation or CLP. Control rats received corresponding vol-
ume(0.4mL)ofvehicle(0.1%DMSOinphosphate-buﬀered
saline). 16hours after sham-operation or CLP, extensor dig-
itorum longus (EDL) muscles were harvested and used for
determination of protein breakdown rates or mRNA and
protein levels for atrogin-1 and MuRF1 as described below.
When the eﬀe c to fc u r c u m i no nN F - κB activity was exam-
ined, muscles were studied 4hours after CLP because we
found in a previous report that the activation of NF-κBi n
skeletalmusclewasmostpronouncedatthattimepoint[14].
In the second series of experiments, muscles were har-
vested from rats 16hours after CLP or sham-operation and
paired muscles were incubated in the absence or presence of
100μMcurcumintodeterminethedirecteﬀectsofcurcumin
on protein breakdown rates, NF-κB activity, p38 activation,
and heat shock protein (hsp) 70 levels.
Animals were treated and cared for in accordance with
National Research Council’s Guide for the Care and Use
of Laboratory Animals. The experimental protocol was ap-
proved by the Institutional Animal Care and Utilization
Committee at the Beth Israel Deaconess Medical Center.
2.2. Muscleincubations
Sixteen hours after CLP or sham-operation, EDL muscles
were gently dissected with intact tendons, mounted on stain-
lesssteelsupportsatrestinglength,andincubatedfor2hours
under physiological conditions in a shaking water bath at
37◦Casdescribedindetailpreviously[28,30].Proteinbreak-
down rates were determined by measuring net release of free
tyrosine into the incubation medium. Because tyrosine is
not synthesized or degraded in muscle tissue and because
reincorporation of tyrosine into protein was prevented by
the presence of cycloheximide (0.5mM) in the medium,
net release of tyrosine provides a reliable measure of pro-
tein breakdown rates. In some experiments, paired muscles
were incubated in absence or presence of curcumin dissolved
in 0.1% DMSO (Cayman Chemical Company, Mich, USA),
cathepsinLinhibitorIV(Calbiochem,EMDBiosciences,San
Diego, Calif, USA), calpeptin, β-lactone (Boston Biochem,
Cambridge, Mass, USA), the p65 inhibitory peptide PTD-
p65-P1 (Imgenex, San Diego, Calif, USA), or quercetin
(Sigma-Aldrich, St Louis, Miss, USA) at concentrations de-
scribed in Section 3.
2.3. Nuclearproteinisolation
Isolated nuclear proteins were used when p65 levels and
p65 activity were determined. Muscle nuclei were isolated
as described previously by Hunter et al. [31] with modiﬁ-
cations. Pooled EDL muscles from 3–5 rats were homog-
enized in ice-cold buﬀer containing 10mM HEPES (pH
7.5), 50mM KCl, 5mM MgCl2, 0.1mM EDTA, 0.5mM
EGTA, and 0.1% Triton X-100. Samples were centrifuged
at 1,000xg for 5minutes at 4◦C. The supernatant (cytoso-
lic fraction) was discarded and extraction buﬀer, contain-
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0.2mM EDTA, and 1.5mM MgCl2, was added to the pellet
(nuclear fraction). Samples were kept on ice for 45minutes
with vigorous vortexing every 5minutes whereafter sam-
ples were centrifuged at 5,300xg for 5minutes at 4◦C. The
supernatants were applied to Amicon Ultra-4 tubes pre-
treated with dilution buﬀer containing 20mM HEPES (pH
7.9), 40mM KCl, 10% glycerol, 0.2mM EDTA, and 1.5mM
MgCl2. After ﬁltration, samples were centrifuged at 7,500xg
for 30minutes at 4◦C. Nuclear protein concentration in the
supernatant was measured according to Bradford [32] using
bovine serum albumin (BSA) as standard.
2.4. Real-timePCR
For determination of atrogin-1 and MuRF1 mRNA levels,
muscleRNAwasextractedandreal-timePCRwasperformed
as described in detail recently [6, 30]. The forward, reverse,
and double-labeled oligonucleotides for atrogin-1 were as
follows,respectively:5 -CTT TCA ACA GAC TGG ACT TCT
CGA-3 ,5  -CAG CTC CAA CAG CCT TAC TAC GT-3 ,a n d
5 -TGC CAT CCT GGA TTC CAG AAG ATT CAA C-3 .T h e
correspondingsequencesforMuRF1were5 -GGACTCCTG
CCG AGT GAC C-3 ,5  -GCG TCA AAC TTG TGG CTC
AG-3 ,a n d5  -AGG AAA ACA GCC ACC AGG TGA AGG
AGG-3 . Ampliﬁcation of 18S rRNA was performed in the
same reaction tubes as an internal standard with an alter-
natively labeled probe (VIC-labeled probe) to distinguish its
product from that derived from atrogin-1 and MuRF1 RNA.
Atrogin-1 and MuRF1 mRNA concentrations were normal-
ized to the 18S mRNA levels. Measurements were performed
in duplicate for each standard and rat muscle sample.
2.5. Isolationof20Sproteasomesandmeasurement
ofproteolyticactivity
Sixteen hours after CLP, paired EDL muscles were harvested
and incubated for 2hours as described above in the ab-
sence or presence of curcumin (100μM). After incubation,
the muscles were rinsed in saline, blotted dry, and frozen in
liquid nitrogen and stored at −80◦C until analysis. To iso-
late 20S proteasomes, muscles were homogenized in ice-cold
buﬀer (pH 7.5) containing 50mM Tris-HCl, 5mM MgCl2,
and 250mM sucrose. The homogenates were subjected to
three sequential centrifugations. The ﬁrst centrifugation was
at 10,000xg for 20minutes. The supernatant was centrifuged
at 100,000 xg for 1hour. The supernatant from this cen-
trifugation was centrifuged at 100,000g for 5hours. The ﬁ-
nal pellet, containing 20S proteasomes, was resuspended in
buﬀer (pH 7.5) containing 50mM Tris-HCl, 5mM MgCl2,
and 20% glycerol. Protein content of the proteasome prepa-
ration was determined according to Bradford [32] using BSA
as standard. The method used here to isolate 20S protea-
someswasusedinapreviousstudyfromourlaboratory[33].
In that study, the isolation of proteasomes was validated by
electron microscopy and by demonstrating that the prote-
olyticactivityintheproteasomefractionwasblockedbypro-
teasome inhibitors.
The activity of the 20S proteosomes was determined by
measuring the cleavage of the ﬂuorogenic substrate succinyl-
leu-leu-val-tyr-7-amido-4-methylcoumarin (LLVY) (Sigma-
Aldrich). This substrate is preferentially hydrolyzed by the
chymotrypsin-like activity of the 20S proteasome. To mea-
sure proteolytic activity, 10μL of the 20S proteasome ex-
tract were added to 50μL of medium containing 50mM
Tris-HCl (pH 8.0), 10mM MgCl2, 1mM 1,4 dithiothreitol,
2U Aypyrase, and 300μML L V Y .T h er e a c t i o nt o o kp l a c e
at 37◦C for 45minutes and was stopped by the addition of
150μL 100% cold ethanol. The peptidase activity was deter-
mined by measuring the generation of the ﬂuorogenic cleav-
age product (methylcoumaryl-amide) at 380nm excitation
wavelength and 440nm emission wavelength with a Spectra-
Max 5 ﬂuorescence spectrophotometer (Molecular Devices,
Union City, Calif, USA).
2.6. Calpainactivity
To test the eﬀe c to fc u r c u m i no nc a l p a i na c t i v i t y ,E D Lm u s -
cles were harvested 16hours after CLP and incubated in the
absence or presence of curcumin (100μM). After 2hours
of incubation, muscles were rinsed in normal saline, blot-
ted dry, frozen in liquid nitrogen, and stored at −80◦C
until analysis. For determination of calpain activity, frozen
muscles were pulverized and homogenized in a buﬀer con-
sisting of 20mM Tris-HCl, (pH 8.0), 5mM EDTA-Tris
(pH 7.2), 0.1% β-mercaptoethanol, 100mg/L trypsin in-
hibitor, 2.5μM E-64, and 2mM serine protease inhibitor
phenyl-methylsulfonylﬂuoride(PMSF).Aftercentrifugation
at 20,000xg for 30minutes at 4◦C, protein concentration in
the supernatant was determined according to Bradford [32]
using BSA as standard.
Calpainactivitywasdeterminedbyaddingaliquotsofsu-
pernatant (40 μg protein) to 160μLo f5 0μM Suc-Leu-Tyr-
7-amino-4-methylcoumarin (SLY) (dissolved in DMSO and
buﬀerconsistingof100mMTris-HCland145mMNaCl,pH
7.3). Incubation was performed at 30◦Cf o r3 0 m i n u t e si n
the absence or presence of 10mM calcium and 400nM of
z-Leu-Leu-Tyr-CHN2, an inhibitor of calpains and cathepsin
L. Amino-4-methylcoumarin release was measured by ﬂuo-
rometry using 360nm excitation and 460nm emission ﬁl-
ters. Calpain activity was deﬁned as the proteolytic activity
at 10mM calcium minus the activity in the presence of cal-
pain inhibitor and absence of calcium. Calpain activity was
expressed in ﬂuorogenic units (FU).
2.7. CathepsinLactivity
Sixteen hours after CLP, paired EDL muscles were incu-
bated for 2hours in the absence or presence of 100μMc u r -
cumin. After incubation, muscles were rinsed with saline,
blotted dry, frozen in liquid nitrogen, and stored at −80◦C
until analysis. Muscles were homogenized in 1% Triton X-
100 in PBS (pH 7.4), and the homogenates were centrifuged
at 10,000xg for 20minutes at 4◦C. Protein concentration in
the supernatant was determined according to Bradford [32];
and aliquots (100 μg protein) were used for measurement
of cathepsin L activity. Cathepsin L activity was determined
by using the ﬂuorogenic peptide substrate Z-Phe-Arg-7-
amido-4-methylcoumarin-HCl and the InnoZyme cathepsin4 Mediators of Inﬂammation
L activity kit (Calbiochem) following the manufacturer’s
instructions. Puriﬁed cathepsin L from human liver (Cal-
biochem) was used as positive control.
2.8. Westernblotting
Aliquots (50μg total cellular protein) of muscle extracts or
nuclear protein extracts were loaded on 7 × 8cm minigels
(Millipore, Badford, Mass, USA). SDS-PAGE was per-
formed on 10% polyacrylamide gels. The separated proteins
were transferred electrophoretically using semidry trans-
fer methodology to nitrocellulose membranes (Millipore).
The membranes were blocked with blocking buﬀer (5%
nonfat dry milk, 50mM Tris-HCl, pH 7.5, 150mM NaCl,
and 1% Tween 20) for 1hour at room temperature. Af-
ter washing with TTBS (50mM Tris-HCl, pH 7.5, 150mM
NaCl, and 1% Tween 20) for 5minutes × 3, membranes
were incubated overnight with one of the following pri-
mary antibodies: polyclonal rabbit antihuman antiphospho
p65 (Ser 536, 1:2000) (Santa Cruz Biotechnology, Santa
Cruz, Calif, USA), polyclonal rabbit anti-human anti-NF-
κB p65 (1:2000), monoclonal mouse antihuman antiphos-
pho p38 MAPK (Thr180/Tyr182, 1:1000), polyclonal rab-
bit antihuman anti-p38 MAPK (1:2000) (Cell signaling,
Danvers, Mass, USA), monoclonal mouse antihuman anti-
Hsp70 (1:2000), polyclonal rabbit antihuman anti-atrogin-1
(1:2000),polyclonalrabbitantihumananti-MuRF1(1:2000),
polyclonal rabbit antihuman anti-OCT-1 (1:2000) (Santa
Cruz Biotechnology), and monoclonal mouse antihuman
anti-α-tubulin antibody (1:1000) (Sigma-Aldrich). After in-
cubation with the primary antibodies, the membranes were
washed with TTBS × 3 and incubated for 1hour with ap-
propriate peroxidase-conjugated secondary antibody. Mem-
branes were then washed exhaustively in TTBS. Immunore-
active protein bands were determined by using the West-
ern Lightning Kit for enhanced chemiluminescence (Perkin-
Elmer Life Sciences, Boston, Mass, USA) and exposed on
Kodak X-Omat blue ﬁlm (Eastman Kodak, Rochester, NY,
USA). The identity of the bands on the Western blots was
conﬁrmed by using a molecular weight ladder.
2.9. NF-κBactivity
NF-κB p65 activity in the nuclear fraction was determined
by using EZ-Detect NF-κB Transcription Factor Kit (Pierce
Biotechnology, Rockford, Ill, USA) and by following the
manufacturer’s instructions. The kit utilizes streptavidin-
coated 96-well plates with bound NF-κB biotinylated con-
sensus sequence and p65 binding is detected by using a p65-
speciﬁc primary antibody and a secondary HRP-conjugated
antibody. Wild type and mutant competitor reactions in-
cluded in the kit were used to ensure signal speciﬁcity and
nuclear extract from TNFα-activated HeLa cells was used as
a positive control.
2.10. Statisticalanalysis
Results are reported as means ±SEM. Statistical analysis was
performed by using Student’s t-test or ANOVA followed by
Holm-Sidak’s or Dunn’s method as appropriate. P<. 05 was
considered statistically signiﬁcant.
3. RESULTS
In previous reports, examining the protective eﬀects of cur-
cumin in skeletal muscle, the dose of the drug varied sub-
stantially, ranging from 10–20 μg/kg [23, 34]t o1 . 7g / k g[ 22].
Studiessuggestthatdosesashighas2g/kgcanbegivenwith-
out toxic eﬀects in rats [35, 36]. In initial experiments in
the present study, we treated rats with three repeated doses
of 60μg/kg each of curcumin administered intraperitoneally.
Because no improvement in muscle protein balance was seen
in those experiments, we instead used curcumin doses cor-
responding to the higher end of the spectrum reported pre-
viously. When rats were treated with total amounts of cur-
cumin ranging from 400 to 1800mg/kg divided into three
doses administered intraperitonelly 1hour before and 8 and
15hours after sham-operation or CLP, a dose-dependent re-
duction of muscle protein breakdown rates was noticed in
septic rats (Figure 1(a)). At the highest dose tested (three
doses of 600mg/kg), the sepsis-induced increase in mus-
cle proteolysis was abolished (Figure 1(b)). Interestingly, the
same dose of curcumin did not inﬂuence protein degrada-
tion in muscles from sham-operated rats, suggesting that
curcumin speciﬁcally aﬀected sepsis-induced muscle prote-
olysis without inﬂuencing basal protein breakdown.
The weight of the EDL muscle was reduced by approx-
imately 14% in septic rats (17.8 ± 0.5v e r s u s2 0 .6 ± 1.1mg
16hours after CLP and sham-operation, resp., means ±SEM
withn = 8 in each group). The corresponding muscle weight
in septic rats treated with three doses of 600mg/kg of cur-
cumin was 19.9 ± 0.9mg, further supporting the concept
thatcurcuminmaypreventsepsis-inducedmusclewasting.It
should be noted, however, that none of these diﬀerences was
statistically signiﬁcant, most likely reﬂecting the fact that the
present septic model is an acute model (16hours). A more
chronic model would be needed to test if curcumin can pre-
vent sepsis-induced loss of muscle (and body) weight. Of
note, in a recent study, four days of curcumin treatment pre-
vented the loss of muscle weight induced by the injection of
1mg/kg of LPS in mice [26].
Muscle wasting during sepsis and other catabolic con-
ditions is typically associated with upregulated expres-
sion of several components of the ubiquitin-proetasome
proteolytic pathway, in particular the ubiquitin ligases
atrogin-1 and MuRF1 [10–12]. In the current study, mRNA
levels for atrogin-1 and MuRF1 in muscles from septic rats
were increased 7 and 9 folds, respectively, above the levels
in muscles from sham-operated rats (Figures 2(a) and 3(a)).
The increase in mRNA levels was accompanied by increased
atrogin-1 and MuRF1 protein levels as determined by West-
ern blotting (Figures 2(b) and 3(b)). Surprisingly, the sepsis-
induced increase in atrogin-1 and MuRF1 expression was
not inﬂuenced by curcumin administered at the same dose
that blocked the sepsis-induced increase in muscle proteoly-
sis (three doses of 600mg/kg).
One of the mechanisms by which curcumin has been re-
ported to exert anti-inﬂammatory and protective eﬀects isVitaliy Poylin et al. 5
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Figure 1: Curcumin inhibits sepsis-induced muscle proteolysis. (a) Rats were treated with diﬀerent doses of curcumin and the inhibition of
muscle protein breakdown in septic rats was calculated as percent inhibition of tyrosine release from muscles of curcumin-treated septic rats
compared with tyrosine release from muscles of vehicle-treated septic rats. Results are from experiments in which 8 septic rats treated with
vehicle and 8 septic rats treated with curcumin were studied for each total dose of curcumin indicated in the ﬁgure. (b) Sham-operated and
septic rats were treated with vehicle (control) or curcumin (total dose 1800 mg/kg divided into three equal doses administered intraperi-
toneally 1 hour before and 8 and 15 hours after sham-operation or CLP). Protein breakdown rates were determined in incubated extensor
digitorum longus muscles 16 hours after sham-operation or CLP by measuring net release of tyrosine. Results are means ±SEM with n = 8
in each group. ∗P<. 05 versus all other groups by ANOVA.
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Figure 2: Sepsis-induced expression of atrogin-1 in extensor digitorum longus muscles is not inﬂuenced by curcumin. Sham-operated and
septic rats were treated with vehicle (control) or curcumin (total dose 1800mg/kg divided into three equal doses administered intraperi-
toneally 1hour before and 8 and 15hours after sham-operation or CLP). Muscles were harvested 16hours after sham-operation or CLP for
(a) atrogin-1 mRNA levels determined by real-time PCR and (b) atrogin-1 protein levels determined by Western blotting. In panel (b), a
representative Western blot is shown in the upper portion and results from densitometric quantiﬁcations are shown in the lower portion of
the ﬁgure. Results are means ±SEM with n = 8 in each group. AU: arbitrary units. ∗P<. 05 versus corresponding sham group by ANOVA.6 Mediators of Inﬂammation
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Figure 3: Sepsis-induced expression of MuRF1 in extensor digitorum longus muscles is not inﬂuenced by curcumin. Sham-operated and
septic rats were treated with vehicle (control) or curcumin (total dose 1800mg/kg divided into three equal doses administered intraperi-
toneally 1hour before and 8 and 15hours after sham-operation or CLP). Muscles were harvested 16hours after sham-operation or CLP
for (a) MuRF1 mRNA levels determined by real-time PCR and (b) MuRF1 protein levels determined by Western blotting. In panel (b), a
representative Western blot is shown in the upper portion and results from densitometric quantiﬁcations are shown in the lower portion of
the ﬁgure. Results are means ±SEM with n = 8 in each group. AU: arbitrary units. ∗P<. 05 versus corresponding sham group by ANOVA.
inhibition of NF-κBa c t i v i t y[ 20, 21]. We reported previ-
ously that NF-κB DNA binding activity in skeletal muscle
was increased after CLP in rats and that this eﬀect of sepsis
was particularly pronounced during the early phase of sep-
sis (4hours after CLP) [14]. Here, we examined the eﬀect
of curcumin (600mg/kg administered 1 hour before CLP)
on NF-κB activity in muscle 4hours after CLP and found
that NF-κB activity, determined as p65 activity in the nu-
clear fraction, was reduced by approximately 30% in septic
rats treated with curcumin (Figure 4(a)). The inhibitory ef-
fect on NF-κB activity was further illustrated by reduced nu-
clearlevelsofphosphorylatedp65incurcumin-treatedseptic
rats (Figure 4(b)). Previous studies provided evidence that
phosphorylation of Ser 536 was associated with activation of
p65 in endotoxemia [37]. In contrast, curcumin treatment
of sham-operated rats did not signiﬁcantly inﬂuence nuclear
p65 activity (Figure 4(c)).
Having established that treatment of rats in vivo with
curcuminblockedthesepsis-inducedincreaseinmusclepro-
teolysis, we next examined whether the drug has a direct ef-
fect in skeletal muscle. This was done by exposing incubated
muscles to curcumin in vitro. When muscles from sham-
operated and septic rats were incubated in the presence of
100μM curcumin, the increased protein degradation seen
in septic muscle was reduced to control levels (Figure 5(a)).
This result is important because it suggests that curcumin
canexertanaboliceﬀectsincatabolicmusclebyadirecteﬀect
and that muscle proteolysis that has already been increased
by sepsis can be reversed by curcumin. Similar to the results
observed in vivo, treatment with curcumin in vitro did not
result in a signiﬁcant inhibition of protein breakdown rates
in muscles from sham-operated rats (Figure 5). Therefore,
in subsequent experiments in the present study, designed to
elucidate mechanisms by which curcumin exerts its eﬀects in
catabolic muscle, we used muscles from septic rats. Because
treatment of incubated muscles from septic rats with diﬀer-
ent concentrations of curcumin suggested that a maximal ef-
fect was achieved with 100μMc u r c u m i n( Figure 5(b)), this
concentration was used in subsequent experiments.
Although the ubiquitin-proteasome pathway plays a sig-
niﬁcant role in muscle protein breakdown in sepsis and a
number of other catabolic conditions [7–9], there is evi-
dence that additional proteolytic mechanisms are involved.
For example, previous studies suggest that calcium-calpain-
dependent cleavage of myoﬁbrillar proteins is an important
“upstream” mechanism of sepsis-induced muscle proteolysis
[5, 6, 38, 39]. Other studies suggest that lysosomal protein
degradation, in particular cathepsin L-dependent proteoly-
sis, is also involved in muscle wasting [3, 4].
The inﬂuence of curcumin on individual proteolytic
pathways is not known from previous studies. In order
to assess the eﬀects of curcumin on proteasomal proteinVitaliy Poylin et al. 7
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Figure 4: Treatment of septic rats with curcumin inhibits NF-
κB/p65 activity in the extensor digitorum longus muscle. Curcumin
(600mg/kg) or vehicle (control) was administered intraperitoneally
1hour before CLP or sham-operation and muscles were harvested
4hours later. Muscles from septic rats were used for determination
of (a) p65 activity and (b) p-p65 levels in the nuclear fraction. (c)
Muscles from sham-operated rats were used for measurement of
p65 activity. Muscles from 2–3 rats were pooled for each measure-
ment. Results are means ±SEM with n = 4 for each group and are
expressed as % of control. ∗P<. 05 versus control by Student’s t-
test.
degradation, incubated muscles from septic rats were treated
with 100μM of the speciﬁc proteaosme inhibitor β-lactone
[40] in the absence or presence of 100μM curcumin. Cal-
culated as the portion of protein degradation that was
blocked by β-lactone, the proteasome-dependent protein
degradationwasreducedbyapproximately45%bycurcumin
(Table 1). In parallel experiments, treatment of incubated
muscles from septic rats with curcumin reduced proteasome
activity by approximately 65% (Figure 6(a)).
In order to assess the eﬀect of curcumin on calpain-
dependentproteindegradation,incubatedmusclesfromsep-
t i cr a t sw e r et r e a t e dw i t h1 0 0 μM of the calpain inhibitor
calpeptin [41] in the absence or presence of 100μMc u r -
cumin.Thecalpain-dependentproteindegradation(thepor-
tion of protein degradation that was inhibited by calpeptin)
was reduced by approximately 50% in the presence of cur-
cumin (Table 1). This eﬀect of curcumin was accompanied
by a 60% inhibition of calpain activity in muscles from sep-
tic rats (Figure 6(b)).
A similar experimental approach was used to determine
the inﬂuence of curcumin on cathepsin L-dependent protein
degradation. When incubated septic muscles were treated
with 100μM of cathepsin L inhibitor IV [42] in the presence
of curcumin, the calculated cathepsin L-dependent protein
degradation was reduced by approximately 40% (Table 1).
In contrast, curcumin did not aﬀect cathepsin L activity in
incubated muscles from septic rats (Figure 6(c)). The rea-
son for these apparently contradictory results with regards to
curcumin-induced inhibition of cathepsin L-dependent pro-
teolysis, but no eﬀect on cathepsin L activity, is not known
at present but may, at least in part, reﬂect nonspeciﬁc eﬀects
of the cathepsin L inhibitor used here [42]. Taken together,
however, the results in Table 1 and Figure 6 suggest that cur-
cumin can reduce the catabolic response to sepsis by inhibit-
ing multiple proteolytic pathways in skeletal muscle.
Because treatment of septic rats with curcumin in vivo
reduced NF-κB/p65 activity in skeletal muscle (Figure 4), we
tested whether a similar mechanism may be involved in the
direct eﬀect of curcumin in septic muscle. When muscles
from septic rats were incubated in the presence of 100μM
curcumin, the nuclear levels of p65 decreased (Figure 7(a))
and p65 DNA binding activity was reduced (Figure 7(b)).
In additional experiments, treatment of incubated muscles
from sham-operated rats did not signiﬁcantly inﬂuence p65
activity (p65 activity was 95 ± 8% of control value in mus-
cles from sham-operated rats treated with 100μMc u r c u m i n
in vitro for 2hours; n = 4 for both control and curcumin-
treated muscles). The results in Figures 7(a) and 7(b) suggest
thattheinhibitionofproteinbreakdowncausedbytreatment
of incubated muscles from septic rats with curcumin may at
least in part reﬂect inhibited NF-κB/p65 activity. In order to
further test the potential role of NF-κB inhibition on protein
breakdown, muscles from septic rats were incubated in the
presence of 100μM of the speciﬁc p65 inhibitor PTD-p65-P1
[43]. This inhibitor consists of a synthetic p65 peptide con-
taining the serine 276 phosphorylation site and linked with
a protein transduction site (PTD), a short protein sequence
that can enter cells to deliver its cargo without any receptor
[43]. Control muscles were treated with 100μM PTD that
was not linked to another peptide. Treatment of the muscles
with PTD-p65-P1 resulted in an approximately 30% reduc-
tion of protein breakdown (Figure 7(c)).
In addition to decreased NF-κB activity, another mech-
anism that may be involved in the eﬀects of curcumin is
inhibition of p38 kinase activity [26, 44] .I no r d e rt ot e s t
the potential role of this mechanism, the levels of phospho-
rylated (activated) p38 (p-p38) were determined in mus-
cles from septic rats incubated in the presence of curcumin.
Treatment of septic muscles with curcumin resulted in re-
duced tissue levels of p-p38, consistent with inhibited p388 Mediators of Inﬂammation
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Figure 5: Treatment of incubated muscles in vitro with curcumin reduces sepsis-induced increase in protein breakdown. (a) Extensor
digitorum longus muscles were harvested from rats 16 hours after sham-operation or CLP and incubated for 2hours in the absence or
presence of curcumin (100μM) dissolved in 0.1% DMSO. Protein breakdown rates were measured as net release of tyrosine as described in
Section 2. Resultsaremeans ±SEM withn = 8ineachgroup. ∗P<. 05versusallother groupsbyANOVA.(b)Incubated muscles fromseptic
rats (16hours after CLP) were treated with diﬀerent concentrations of curcumin for 2hours followed by measurement of tyrosine release.
Results are means ±SEM with n = 8 in each group except for “0 curcumin” which was pooled from 3 paired experiments (0 versus 50, 0
versus 100, and 0 versus 500μM). Results are expressed as % of control.
Table 1: The eﬀects of curcumin on protein breakdown by diﬀerent proteolytic pathways in incubated EDL muscles from septic rats. EDL
muscles from septic rats were incubated in the absence or presence of speciﬁc proteolytic inhibitors. The inhibition of protein degradation
caused by an inhibitor was calculated as the portion of protein degradation regulated by that speciﬁc proteolytic pathway. All diﬀerences
caused by the proteolytic inhibitors as well as all diﬀerences induced by curcumin were statistically signiﬁcant (P<. 05) by ANOVA. Results
are means ±SEM with n = 7 in each group.
Inhibitor Protein degradation (nmol tyr/g ww ×2h) Inhibition by curcumin
No curcumin Curcumin
No addition 230 ±11 160 ±9
β-lactone (100μM) 164 ±9 124 ±9
Proteasomal degradation 66 36 −45%
No addition 200 ±13 145 ±13
Calpeptin (100μM) 125 ±9 108 ±14
Calpain-dependent degradation 75 37 −51%
No addition 235 ±6 171 ±8
Cathepsin L Inhibitor IV (100μM) 121 ±3 106 ±5
Lysosomal degradation 114 65 −43%
activity (Figures 8(a) and 8(b)). The potential role of p38
in the regulation of muscle proteolysis was further tested
by treating incubated muscles from septic rats with the
p38 inhibitor SB202190. This drug speciﬁcally reduces the
activity of p38γ, the predominant p38 isoform in skele-
t a lm u s c l e[ 45, 46]. Treatment of incubated muscles from
septic rats with 50μM SB202190 resulted in an approx-
imately 30% inhibition of protein breakdown (data not
shown).
In previous studies, curcumin induced the heat shock
response as determined by the induction of hsp70 expres-
sion [47]. We next tested whether a similar mechanism
may be involved in the eﬀects of curcumin observed in
the present experiments. When muscles from septic rats
were incubated in the presence of 100μM curcumin, no
changes in hsp70 levels were noticed (Figure 9(a)). In ad-
dition, the heat shock inhibitor quercetin [48] did not in-
ﬂuence the eﬀect of curcumin on protein degradation in
muscles from septic rats (Figure 9(b)). Thus, induction of
the heat shock response is probably not a major mechanism
by which curcumin inhibits sepsis-induced muscle proteoly-
sis.Vitaliy Poylin et al. 9
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Figure 6: Treatment of incubated muscles from septic rats with
curcumin inhibits 20S proteasome and calpain activity but does
not inﬂuence cathepsin L activity. Extensor digitorum longus mus-
cles were harvested from rats 16hours after CLP and incubated for
2hours in the absence or presence of curcumin (100μM) followed
by measurement of (a) 20S proteasome activity, (b) calpain activ-
ity, and (c) cathepsin L activity as described in Section 2.R e s u l t s
are means ±SEM with n = 6 in each group. FU: ﬂuorogenic units.
∗P<. 05 versus control by Student’s t-test.
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Figure 7: (a) p65 levels determined by Western blotting and (b)
p65 activity in the nuclear fraction of extensor digitorum longus
muscles from septic rats incubated for 2 hours in the absence or
presence of 100μM curcumin. Results are means ±SEM with n = 4
in each group. AU: arbitrary units. ∗P<. 05 versus control by Stu-
dent’st-test.(c)Theeﬀectofthep65inhibitorPTD-p65-P1onpro-
teinbreakdownratesinincubatedmusclesfromsepticrats.Muscles
were incubated in the presence of 100μM PTD-p65-P1 or 100μM
of the inactive peptide PTD as control. Results are means ±SEM
with n = 7 in each group. ∗P<. 05 versus PTD by Student’s t-test.
4. DISCUSSION
Inthepresentstudy,treatmentofratswithcurcuminblocked
sepsis-induced increase in muscle proteolysis. In additional
experiments, treatment of incubated muscles from septic
rats with curcumin in vitro resulted in inhibited proteaso-
mal, cathepsin L-dependent, and calpain-dependent protein
degradation, suggesting that curcumin can inhibit multiple10 Mediators of Inﬂammation
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Figure 8: (a) Western blot analysis of phosphorylated and total p38
in septic extensor digitorum longus muscles incubated for 2 hours
in the absence (control) or presence of 100μM curcumin. Muscle
levels of α-tubulin were determined for loading control. Similar
results were observed in four repeated experiments. (b) Quantiﬁ-
cation of p-p38 Western blots by densitometry. Results are means
±SEM with n = 4 in each group. ∗P<. 05 versus control by Stu-
dent’s t-test.
proteolytic pathways by a direct eﬀect in catabolic muscle.
Theresultsareimportantbecausetheysuggestthatcurcumin
may be useful in the prevention and treatment of muscle
wasting caused by sepsis. In a recent study, curcumin pre-
vented metabolic consequences of sepsis in the liver and
prevented mortality in rats with sepsis induced by CLP [49].
The role of curcumin in the treatment of sepsis was reviewed
recently by Thiemermann [50].
Thedoseofcurcuminusedinthepresentstudywashigh,
in particular if the dose is converted to a corresponding dose
in humans (each dose of 600mg/kg administered in rats in
the present study would correspond to 42g in a 70-kg per-
son). It should be noted that the optimal dose of curcumin is
not clear, probably reﬂecting diﬀerences in route of admin-
istration, length of treatment, and disease state being treated
[51]. In a recent report, up to 12g of curcumin was adminis-
tered in humans without signiﬁcant toxicity [52].
Because, in the present in vivo experiments, rats received
the ﬁrst dose of curcumin before induction of sepsis, the re-
sults may have reﬂected prevention, rather than treatment,
of the sepsis-induced muscle proteolysis. An even more ex-
tended period of pretreatment (4days) was used in a re-
cent study in which curcumin prevented LPS-induced mus-
cle wasting [26]. The results from the in vitro experiments in
the present study are important because they demonstrate
that muscle proteolysis that has already been activated by
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Figure 9: The heat shock response is not involved in the eﬀects of
curcumin on protein breakdown in incubated muscles from septic
rats. (a) Muscles from septic rats (16 hours after CLP) were incu-
bated for 2hours in the absence (control) or presence of 100μM
curcumin followed by determination of hsp-70 levels by Western
blotting. Similar results were observed in three repeated experi-
ments. (b) Protein breakdown rates in muscles from septic rats in-
cubated for 2hours in the absence or presence of 100μM curcumin
or100μMcurcumin+100mMquercetin.Resultsaremeans ±SEM
with n = 12 in each group. ∗P<. 05 versus control by ANOVA.
sepsis can be reversed by curcumin. Although any extrap-
olation from that observation needs to be done with cau-
tion, the result suggests that it may be possible to treat, and
not only prevent, sepsis-induced muscle proteolysis. How-
ever, additional experiments, delaying curcumin therapy in
vivoforseveralhoursafterinductionofsepsis,willbeneeded
tofurthertesttheroleofcurcumininthetreatmentofsepsis-
induced muscle wasting.
A pronounced increase in atrogin-1 and MuRF1 mRNA
levels in skeletal muscle as observed in septic rats in the
presentstudyissimilartoresultsinpreviousreportsinwhich
the expression of the ubiquitin ligases was upregulated in
various catabolic conditions, including sepsis, denervation,
starvation, and burn injury [10–12, 53]. Because atrogin-1
and MuRF1 mRNA levels have been suggested to be reli-
able molecular markers of muscle wasting, it was surpris-
ing in the current experiments that atrogin-1 and MuRF1
mRNA levels were not reduced in curcumin-treated sep-
tic rats despite inhibited muscle protein breakdown rates. A
similar “disconnection” between changes in protein break-
down rates and changes in atrogin-1 and MuRF1 expres-
sion has been reported in other studies as well. For exam-
ple, we found recently that treatment of rats with calpain
inhibitors prevented sepsis-induced muscle proteolysis but
did not inﬂuence the elevated mRNA levels for atrogin-
1a n dM u R F 1[ 30]. In other experiments, muscle-speciﬁcVitaliy Poylin et al. 11
overexpression of active IKKβ resulted in increased muscle
proteolysis and upregulated MuRF1 expression but did not
inﬂuence atrogin-1 expression [17]. In a more recent study,
treatment of mice with curcumin prevented LPS-induced
muscle atrophy and atrogin-1 expression but did not aﬀect
MuRF1 expression [26]. Thus, although there is a close cor-
relationbetweenmuscleproteinbreakdownratesandtheex-
pressionofatrogin-1andMuRF1inmanysituations,thecor-
relation is not universal.
O n l yo n ep r e v i o u ss t u d yh a sb e e nr e p o r t e di nw h i c h
the eﬀects of curcumin on the catabolic response in mus-
cle during a sepsis-like condition were tested [26]. In that
study, mice were treated for 4days with intraperitoneal in-
jections of curcumin (10–60μg/kg) followed by the injection
of 1mg/kg of LPS. The pretreatment with curcumin resulted
in a dose-dependent inhibition of LPS-induced upregulation
of atrogin-1, but not MuRF1, and loss of muscle weight and
protein.Theexperimentsreportedherediﬀerfromtheprevi-
ous study in endotoxemic mice in several important aspects.
First, CLP is a septic model that resembles the situation in
many patients with abdominal sepsis and, therefore, may be
clinically more relevant than a single injection of LPS. Sec-
ond, whereas in the study of endotoxemic mice [26], the ex-
perimental protocol was that of curcumin pretreatment only
(with no further administration of curcumin after the injec-
tionofLPS).Inthepresentstudy,ratscontinuedtobetreated
with curcumin during the septic course. Finally, the current
experiments provided further insight into cellular mecha-
nisms by determining the inﬂuence of curcumin treatment
onindividualproteolyticpathways.Despitethesediﬀerences,
however, both studies support the concept that the catabolic
responsetosepsisandendotoxemiamaybepreventedbycur-
cumin.
Although curcumin can inhibit NF-κBa c t i v a t i o nb y
preventing the phosphorylation and degradation of IkBα
[20, 21] and is frequently used as an “NF-κB inhibitor,” the
drug can exert other anti-inﬂammatory eﬀects as well, in-
cluding inhibition of p38 kinase activity [26, 44], oxygen
radical scavenging [54], and induction of the heat shock re-
sponse [47]. Interestingly, the mechanisms by which cur-
cumin provide protection may be diﬀerent depending on
the insult and the dose of curcumin. For example, the re-
sults in the present study suggest that curcumin (600mg/kg
administered 1hour before CLP) prevented the early activa-
tion of NF-κB in septic rats whereas 60μg/kg of the drug,
administered daily to mice during 4days before a single in-
jection of LPS, did not inhibit NF-κB DNA binding activ-
ity but instead exerted its protective eﬀects by inhibiting p38
kinase activity [26]. It should be pointed out that although
NF-κB activity (determined as p65 nuclear activity) was in-
hibited by treatment with curcumin and the p65 inhibitor
PTD-p65-P1 reduced protein breakdown in septic muscles
in the present study, the results do not prove that the re-
duction of muscle proteolysis was caused by NF-κB inhibi-
tion. Indeed, the fact that NF-κBi sa c t i v a t e de a r l y( 4h o u r s
a f t e rC L P )i nt h ep r e s e n ts e p t i cm o d e l[ 14] and that pro-
tective eﬀects of curcumin treatment were present up to at
least 16 hours after induction of sepsis suggests that other
mechanisms may have been involved as well. Results in the
present study suggest that inhibition of p38 activity may
be an additional mechanism by which curcumin blocked
sepsis-induced muscle proteolysis, similar to the mechanism
in curcumin-treated mice with endotoxemia [26]. Because,
in recent experiments, we found that incubation of muscles
from septic rats with the oxygen radical scavenger 2,6-di-
tertbutyl-4-methylphenol did not reduce protein breakdown
rates [30], it is unlikely that the eﬀects of curcumin noted
here were caused by oxygen radical scavenging. Of note, the
present results do not rule out the possibility that mecha-
nisms other than or in addition to NF-κB and p38 inhibition
were involved in the anticatabolic eﬀects of curcumin.
Despite substantial progress during the last 10–20years
in our understanding of mechanisms involved in the regu-
lation of muscle mass, a universally accepted and eﬀective
treatment of muscle wasting is still not available. The results
in the present study suggest that curcumin may be used to
prevent or treat muscle catabolism, at least when caused by
sepsis. This is signiﬁcant because curcumin can be admin-
istered orally or parenterally at high doses without toxic ef-
fects [19, 34, 35, 51, 52, 55]. It should be noted, however,
that before any clinical implications from the present results
are made, several limitations of the current study need to be
taken into account. First, the experiments were performed in
septic rats and further studies will be needed to test if cur-
cumin can improve protein balance in human patients with
sepsis. Second, even if the present in vitro experiments sug-
gest that changes in muscle protein breakdown that have al-
ready been induced by sepsis can be reversed by curcumin,
our in vivo experiments do not allow us to conclude that
curcumin can be used as treatment, rather than prevention,
of muscle wasting. Finally, although the present observations
suggest that the eﬀects of curcumin on muscle proteolysis
in sepsis may be related to inhibition of NF-κB and p38
activity, additional studies are needed to establish the link
between these mechanisms and reduced muscle proteolysis.
5. CONCLUSIONS
The present results suggest that curcumin can reduce sepsis-
induced muscle wasting by inhibiting multiple proteolytic
pathways.Theﬁndingthatatrogin-1andMuRF1mRNAlev-
els remained high in septic rats treated with curcumin, de-
spite inhibited muscle protein breakdown rates, suggests that
there is not an absolute correlation between changes in mus-
cle proteolysis and changes in atrogin-1 and MuRF1 expres-
sion during treatment of muscle wasting. Although inhibi-
tion of NF-κB activity is probably an important mechanism,
curcumin may prevent loss of muscle mass by other mecha-
nisms as well, including inhibition of p38 kinase activity. The
observations in the present study are important because they
ma yhelpdev elopnewstrat egiesforthepr ev entionandtr eat-
ment of muscle wasting during sepsis and other catabolic
conditions.
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